Elana Cherry

667 citations
16 papers · 509 · h-index 14

Impact in

  • Virology top 5%
    • HIV Research and Treatment
  • Immunology top 10%
    • Biosimilars and Bioanalytical Methods

Papers in

  • Virology 5
    • HIV Research and Treatment 5
  • Immunology 9
    • Biosimilars and Bioanalytical Methods 9
Co-authors
Ivan Babić (1 shared paper)Daishi Fujita (1 shared paper)Mark A. Wainberg (3 shared papers)Chen Liang (2 shared papers)Lawrence Kleiman (2 shared papers)Liwei Rong (1 shared paper)Michael Laughrea (1 shared paper)Nathalie Morin (2 shared papers)
Journals
Bioanalysis (9 papers)Journal of Virology (2 papers)Oncogene (1 paper)AIDS Research and Human Retroviruses (1 paper)AIDS (1 paper)
Partner nations
CanadaUnited StatesGermany

In The Last Decade

Elana Cherry

16 papers receiving 480 citations

Peers

Elana Cherry
Comparison fields: 5 of 60
  • Virology 91
  • Immunology 244
  • Biophysics 35
  • Infectious Diseases 87
  • Oncology 87
Replace Zhenhao Fang with:
Zhenhao Fang United States
Stephanie Fraser United States
Cliburn Chan United States
Anjali Seth United States
Denise M. O’Hara United States
Johan Vandersmissen Belgium
Karine Bernard France
Paula M. Krosky United States
Ameya Sinha Singapore
Marijana Ručević United States
Elana Cherry relative to Zhenhao Fang United States Zhenhao Fang's profile →
Citations per field
00.5×2×3×4×5×
Zhenhao Fang · 1×
Citations per year

Countries citing papers authored by Elana Cherry

Since Specialization
Citations

This map shows the geographic impact of Elana Cherry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elana Cherry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elana Cherry more than expected).

Fields of papers citing papers by Elana Cherry

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elana Cherry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elana Cherry. The network helps show where Elana Cherry may publish in the future.

Co-authors

The 17 scholars most cited alongside Elana Cherry, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Elana Cherry Line = papers co-authored together Elana Cherry links everyone, so they are left out of the graph.

All Works

16 of 16 papers shown
#Work
1
2019 White Paper on Recent Issues in Bioanalysis: FDA Immunogenicity Guidance, Gene Therapy, Critical Reagents, Biomarkers and Flow Cytometry Validation (Part 3 – Recommendations on 2019 FDA Immunogenicity Guidance, Gene Therapy Bioanalytical Challenges, Strategies for Critical Reagent Management, Biomarker Assay Validation, Flow Cytometry Validation & CLSI H62)
Bioanalysis ·Steven P. Piccoli, Devangi S. Mehta, Alessandra Vitaliti, John L. Allinson, Shashi Amur, Steve Eck, Cherie C. Green, Michael Nathan Hedrick
201978
2
SUMO modification of Sam68 enhances its ability to repress cyclin D1 expression and inhibits its ability to induce apoptosis
Oncogene ·Ivan Babić, Elana Cherry, Daishi Fujita
200665
3
2020 White Paper on Recent Issues in Bioanalysis: Vaccine Assay Validation, qPCR Assay Validation, QC for CAR-T Flow Cytometry, NAb Assay Harmonization and ELISpot Validation ( Part 3 –Recommendations on Immunogenicity Assay Strategies, NAb Assays, Biosimilars and FDA/EMA Immunogenicity Guidance/Guideline, Gene & Cell Therapy and Vaccine Assays)
Bioanalysis ·Bart Corsaro, Tong‐Yuan Yang, Rocio D. Murphy, Ivo Sonderegger, Andrew Exley, Sylvie Bertholet, Naveen K. Dakappagari, Francis J. Dessy
202152
4
2018 White Paper on Recent Issues in Bioanalysis: Focus on Flow Cytometry, Gene Therapy, Cut Points and Key Clarifications on Bav (Part 3 – Lba/Cell-Based Assays: Immunogenicity, Biomarkers and Pk Assays)
Bioanalysis ·Lauren F. Stevenson, Susan M. Richards, Renuka C. Pillutla, Albert Torri, John Kamerud, Devangi S. Mehta, Stephen Keller, Shobha Purushothama
201850
5
2018 White Paper on Recent Issues in Bioanalysis: ‘A Global Bioanalytical Community Perspective on Last Decade of Incurred Samples Reanalysis (ISR)’ (Part 1 – Small Molecule Regulated Bioanalysis, Small Molecule Biomarkers, Peptides & Oligonucleotide Bioanalysis)
Bioanalysis ·Jan Welink, Yuanxin Xu, Eric Yang, Amanda Wilson, Neil Henderson, Lina Luo, Stephanie Fraser, Uma Kavita
201837
6
2018 White Paper on Recent Issues in Bioanalysis: Focus on Immunogenicity Assays by Hybrid LBA/LCMS and Regulatory Feedback (Part 2 – PK, PD & ADA Assays by Hybrid LBA/LCMS & Regulatory Agencies’ Inputs on Bioanalysis, Biomarkers and Immunogenicity)
Bioanalysis ·Hendrik Neubert, Timothy V. Olah, Anita Lee, Stephanie Fraser, Robert W. Dodge, Omar Laterza, Matthew E. Szapacs, Stephen C. Alley
201834
7
2021 White Paper on Recent Issues in Bioanalysis: TAb/NAb, Viral Vector CDx, Shedding Assays; CRISPR/Cas9 & CAR-T Immunogenicity; PCR & Vaccine Assay Performance; ADA Assay Comparability & Cut Point Appropriateness ( Part 3 – Recommendations on Gene Therapy, Cell Therapy, Vaccine Assays; Immunogenicity of Biotherapeutics and Novel Modalities; Integrated Summary of Immunogenicity Harmonization)
Bioanalysis ·LiNa Loo, Shannon Harris, Mark Milton, Meena Meena, Wibke Lembke, Flora Berisha, Sylvie Bertholet, Francis J. Dessy
202228
8
Deletion Mutagenesis within the Dimerization Initiation Site of Human Immunodeficiency Virus Type 1 Results in Delayed Processing of the p2 Peptide from Precursor Proteins
Journal of Virology ·Chen Liang, Liwei Rong, Elana Cherry, Lawrence Kleiman, Michael Laughrea, Mark A. Wainberg
199927
9
2019 White Paper On Recent Issues in Bioanalysis: FDA BMV Guidance, ICH M10 BMV Guideline and Regulatory Inputs ( Part 2 – Recommendations on 2018 FDA BMV Guidance, 2019 ICH M10 BMV Draft Guideline and Regulatory Agencies' Input on Bioanalysis, Biomarkers and Immunogenicity)
Bioanalysis ·Brian P. Booth, Lauren F. Stevenson, Renuka C. Pillutla, Michael H. Buonarati, Christopher Beaver, Daniela Fraier, Fabio Garofolo, Sam H. Haidar
201924
10
2021 White Paper on Recent Issues in Bioanalysis: Mass Spec of Proteins, Extracellular Vesicles, CRISPR, Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1; Non-Liquid & Rare Matrices; Regulatory Inputs ( Part 1A – Recommendations on Endogenous Compounds, Small Molecules, Complex Methods, Regulated Mass Spec of Large Molecules, Small Molecule, PoC & Part 1B - Regulatory Agencies' Inputs on Bioanalysis, Biomarkers, Immunogenicity, Gene & Cell Therapy and Vaccine)
Bioanalysis ·Surinder Kaur, Stephen C. Alley, Matt Szapacs, Amanda Wilson, Eugene Ciccimaro, Dian Su, Neil Henderson, Linzhi Chen
202223
11
2020 White Paper on Recent Issues in Bioanalysis: BAV Guidance, CLSI H62, Biotherapeutics Stability, Parallelism Testing, CyTOF and Regulatory Feedback ( Part 2A –Recommendations on Biotherapeutics Stability, PK LBA Regulated Bioanalysis, Biomarkers Assays, Cytometry Validation & Innovation Part 2B –Regulatory Agencies’ Inputs on Bioanalysis, Biomarkers, Immunogenicity, Gene & Cell Therapy and Vaccine)
Bioanalysis ·Susan M. Spitz, Yan Zhang, Sally K. Fischer, Kristina McGuire, Ülrike Sommer, Lakshmi S. Amaravadi, Abbas Bandukwala, Steven Eck
202122
12
Neutralizing Antibodies Directed against the V3 Loop Select for Different Escape Variants in a Virus with Mutated Reverse Transcriptase (M184V) Than in Wild-Type Human Immunodeficiency Virus Type 1
AIDS Research and Human Retroviruses ·Phil Inouye, Elana Cherry, Mayla Hsu, Susan Zolla‐Pazner, MARK A. WAINBERG
199816
13
Effect of HIV constructs containing protease-reverse transcriptase fusion proteins on viral replication
AIDS ·Elana Cherry, Nicolas Morin, Mark A. Wainberg
199816
14
Mutations at codon 184 in simian immunodeficiency virus reverse transcriptase confer resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine
Antimicrobial Agents and Chemotherapy ·Elana Cherry, Margaret R. Slater, Horacio Salomón, Erling W. Rud, Mark A. Wainberg
199714
15
The roles of the human immunodeficiency virus type 1 Pol protein and the primer binding site in the placement of primer tRNA(3Lys) onto viral genomic RNA
Journal of Virology ·Chen Liang, Libin Rong, Nathalie Morin, Elana Cherry, Yue Huang, Lawrence Kleiman, Mark A. Wainberg
199714
16
Cotransfection of mutated forms of human immunodeficiency virus type 1 Gag-Pol with wild-type constructs can interfere with processing and viral replication.
PubMed ·Nathalie Morin, Elana Cherry, Xian Chang Li, Wainberg Ma
19999

About Elana Cherry

Elana Cherry is a scholar working on Virology, Immunology, Infectious Diseases, Biophysics and Oncology, having authored 16 papers that have together received 509 indexed citations. Recurring topics across this work include Biosimilars and Bioanalytical Methods (9 papers), HIV Research and Treatment (5 papers), Biosensors and Analytical Detection (5 papers), Advanced Biosensing Techniques and Applications (4 papers), CAR-T cell therapy research (4 papers), HIV/AIDS drug development and treatment (4 papers), Virus-based gene therapy research (2 papers) and Cell Image Analysis Techniques (2 papers). The work is most often cited by research in Virology (91 citations), Immunology (244 citations), Biophysics (35 citations), Infectious Diseases (87 citations) and Oncology (87 citations). Elana Cherry has collaborated with scholars based in Canada, United States and Germany. Frequent co-authors include Ivan Babić, Daishi Fujita, Mark A. Wainberg, Chen Liang, Lawrence Kleiman, Liwei Rong, Michael Laughrea, Nathalie Morin, Horacio Salomón and Susan Zolla‐Pazner. Their work appears in journals such as Bioanalysis, Journal of Virology, Oncogene, AIDS Research and Human Retroviruses and AIDS.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zhenhao FangBreakdown of academic impact, for papers by Stephanie FraserBreakdown of academic impact, for papers by Cliburn ChanBreakdown of academic impact, for papers by Anjali SethBreakdown of academic impact, for papers by Denise M. O’HaraBreakdown of academic impact, for papers by Johan VandersmissenBreakdown of academic impact, for papers by Karine BernardBreakdown of academic impact, for papers by Paula M. KroskyBreakdown of academic impact, for papers by Ameya SinhaBreakdown of academic impact, for papers by Marijana Ručević